We are live on ! Find out more
MGX icon

Metagenomi Therapeutics
MGX

56 hedge funds and large institutions have $11M invested in Metagenomi Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

2.04% more ownership

Funds ownership: 15.99% → 18.02% (+2%)

3% less funds holding

Funds holding: 58 → 56 (-2)

23% less capital invested

Capital invested by funds: $14.2M → $11M (-$3.21M)

28% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 18

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
56
Holders Change
-2
Holders Change %
-3.45%
% of All Funds
0.68%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
11
Increased
13
Reduced
18
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$999K
2
Jane Street
Jane Street
New York
+$726K
3
Two Sigma Investments
Two Sigma Investments
New York
+$506K
4
BCM
Bridgeway Capital Management
Texas
+$433K
5
Citadel Advisors
Citadel Advisors
Florida
+$386K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$393K
2
Walleye Capital
Walleye Capital
New York
-$169K
3
Millennium Management
Millennium Management
New York
-$163K
4
JP Morgan Chase
JP Morgan Chase
New York
-$132K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$81K
Name Holding Trade Value Shares
Change 		Change in
Stake
QC
26
Quadrature Capital
United Kingdom
$54.9K +$73.4K +33,917 New
PAM
27
Panagora Asset Management
Massachusetts
$52.8K +$70.5K +32,580 New
Point72 Asset Management
28
Point72 Asset Management
Connecticut
$43.1K +$57.6K +26,589 New
UBS Group
29
UBS Group
Switzerland
$40.7K +$3.49K +1,611 +7%
DTL
30
Dynamic Technology Lab
Singapore
$38K -$7.39K -3,416 -13%
VPIM
31
Vanguard Personalized Indexing Management
California
$26.4K -$11.3K -5,224 -24%
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$22.3K +$29.8K +13,783 New
PPG
33
Peak Planning Group
Colorado
$20.3K +$27.1K +12,500 New
TSS
34
Two Sigma Securities
New York
$19K -$1.06K -489 -4%
LPL Financial
35
LPL Financial
California
$18.3K +$24.5K +11,297 New
Squarepoint
36
Squarepoint
New York
$17.2K +$22.9K +10,594 New
HF
37
HRT Financial
New York
$17K -$6.51K -3,006 -21%
TRCT
38
Tower Research Capital (TRC)
New York
$15.1K +$20.1K +9,303 New
Russell Investments Group
39
Russell Investments Group
United Kingdom
$11.6K – – –
Fidelity Investments
40
Fidelity Investments
Massachusetts
$11K -$7.33K -3,388 -33%
MAM
41
Meeder Asset Management
Ohio
$8.9K – – –
US Bancorp
42
US Bancorp
Minnesota
$7.29K – – –
Osaic Holdings
43
Osaic Holdings
Arizona
$4.68K -$541 -250 -8%
JP Morgan Chase
44
JP Morgan Chase
New York
$2.58K -$132K -60,963 -97%
MPWT
45
MassMutual Private Wealth & Trust
Connecticut
$961 – – –
Nisa Investment Advisors
46
Nisa Investment Advisors
Missouri
$828 – – –
Jones Financial Companies
47
Jones Financial Companies
Missouri
$810 – – –
AF
48
Allworth Financial
California
$810 +$1.08K +500 New
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$497 -$32.2K -14,864 -98%
LFG
50
Larson Financial Group
Missouri
$81 – – –
1
2
3

MGX Hedge Fund Activity: Q4 2025 in Review

56 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q4 2025, worth a combined $11M — down 23% from $14.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new MGX positions and 9 closed out — a net gain of 2 holders — while 13 added to existing stakes and 18 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $999K. The largest seller was Morgan Stanley, cutting an estimated $393K.

  • 56 institutional investors held Metagenomi Therapeutics (MGX) as of Q4 2025, down from 58 in Q3 2025.
  • Funds reported $11M of Metagenomi Therapeutics stock for Q4 2025, down 23% quarter-over-quarter.
  • 11 funds opened new Metagenomi Therapeutics positions in Q4 2025 and 9 closed out, a net change of +2 holders.
  • The largest Metagenomi Therapeutics buyer in Q4 2025 was Renaissance Technologies, an estimated $999K added.
  • The largest Metagenomi Therapeutics seller in Q4 2025 was Morgan Stanley, an estimated $393K sold.

Based on aggregated 13F filings for Q4 2025.